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Behavioral/Cognitive
The Role of the Hypothalamic Paraventricular Nucleus and
the Organum Vasculosum Lateral Terminalis in the Control
of Sodium Appetite in Male Rats
Laura A. Grafe,1 Anne E. Takacs,2Daniel K. Yee,3 and Loretta M. Flanagan-Cato1,2,4
1Neuroscience Graduate Group, Departments of 2Psychology and 3Animal Biology, and the 4Mahoney Institute of Neurological Sciences, University of
Pennsylvania, Philadelphia Pennsylvania 19104
Angiotensin II (AngII) and aldosterone cooperate centrally to produce a robust sodiumappetite. The intracellular signaling and circuitry
that underlie this interaction remain unspecified. Male rats pretreated with both deoxycorticosterone (DOC; a synthetic precursor of
aldosterone) andcentralAngII exhibitedamarked sodium intake, as classically described.Disruptionof inositol trisphosphate signaling,
but not extracellular-regulated receptor kinase 1 and 2 signaling, prevented the cooperativity of DOC and AngII on sodium intake. The
pattern of expression of the immediate early gene product cFos was used to identify key brain regions thatmay underlie this behavior. In
the paraventricular nuclei (PVN) of the hypothalamus, DOC pretreatment diminished both AngII-induced cFos induction and neurose-
cretionofoxytocin, apeptide expressed in thePVN.Conversely, in theorganumvasculosumlateral terminalis (OVLT),DOCpretreatment
augmented cFos expression. Immunohistochemistry identified a substantial presence of oxytocin fibers in the OVLT. In addition, when
action potentials in the PVNwere inhibitedwith intraparenchymal lidocaine, AngII-induced sodium ingestionwas exaggerated. Intrigu-
ingly, this treatment also increased thenumber of neurons in theOVLTexpressingAngII-induced cFos. Collectively, these results suggest
that the behavioral cooperativity between DOC and AngII involves the alleviation of an inhibitory oxytocin signal, possibly relayed
directly from the PVN to the OVLT.
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Introduction
The hormones angiotensin (AngII) and aldosterone are key de-
fenders of electrolyte balance, blood volume, and blood pressure
(Peach, 1977). In the event of sodium depletion, hypovolemia,
and/or hypotension, AngII and aldosterone are produced, which
engage homeostatic responses, including a prodigious drive for
sodium consumption (Ganong, 1977). Exogenous administra-
tion of either hormone alone produces a modest sodium intake;
however, combined treatments result in markedly greater so-
dium consumption (Fluharty and Epstein, 1983), suggesting co-
operative neural mechanisms. Steady progress has been made in
revealing the independent natriorexic effects of AngII and aldo-
sterone; however, the mechanism for the cooperative actions of
AngII and aldosterone to promote a greater than additive effect
on sodium ingestion remains unclear.
An intriguing model has been proposed to explain the syner-
gistic actions of AngII and aldosterone on sodium ingestion
based on disinhibition (Stricker and Verbalis, 1987; Blackburn et
al., 1992a). In particular, central AngII activates oxytocin neu-
rons in the paraventricular nuclei (PVN) and supraoptic nuclei
(SON; Akaishi et al., 1980). Given that centrally released oxytocin
suppresses sodium ingestion, AngII would be expected to elicit
limited salt intake. Pretreatmentwith amineralocorticoid dimin-
ishes AngII-induced oxytocin neuronal activation (Stricker and
Verbalis, 1996, 2004; Roesch et al., 2001), thereby disinhibiting
natriorexia. The exact role of oxytocin in the aldosterone-AngII
interaction on sodiumappetite remains unclear (Blackburn et al.,
1992a; Fitts et al., 2003; Rigatto et al., 2003). In particular, the
brain region in which oxytocin acts to inhibit sodium appetite is
unknown.
A variety of studies have provided insight into the behavioral
and endocrine effects of AngII. Circulating AngII binds to AngII
type 1 receptors (AT1R) in the subfornical organ (SFO) and or-
ganum vasculosum lateral terminalis (OVLT), brain regions with
an incomplete blood–brain barrier (Ganong, 1984). The SFO
andOVLT relay information to the PVNand SON (Miselis, 1981;
McKinley et al., 1992b) to prompt secretion of arginine vasopres-
sin (AVP) and oxytocin (Bisset et al., 1971). The AT1R is a hep-
tahelical receptor that triggers inositol 1,4,5-triphosphate (IP3)
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production and Ca2mobilization (Smith et al., 1984; Enjalbert
et al., 1986; Taylor et al., 1990; Beresford and Fitzsimons, 1992).
In parallel, mitogen-activated protein kinase kinase (MEK) be-
comes phosphorylated, which activates the p42 and p44 isoforms
of mitogen-activated protein kinase, also referred to as extracel-
lular signal-regulated kinase 1 and 2 (ERK1/2; Sadoshima et al.,
1995). IP3 signaling mediates AngII-induced thirst, whereas the
ERK1/2 signaling pathway mediates sodium appetite (Daniels et
al., 2005, 2009; Felgendreger et al., 2013). It is unclear whether
these AngII-induced signal transduction pathways are affected by
mineralocorticoids in brain targets.
To investigate the model of Aldo-AngII-oxytocin control of
sodium appetite, we took a multidisciplinary approach investi-
gating signal transduction, functional neuroanatomy, and re-
versible lesions. Initial results were inconsistentwith the view that
mineralocorticoids simply amplify the signaling effects of AngII.
Subsequent findings implicated an inhibitory oxytocinergic link be-
tween the PVN and the OVLT. Together, these results confirm and
extend the working model that the aldosterone-AngII cooperative
effect on sodium appetite involves hypothalamic disinhibition.
Materials andMethods
Animals.Adultmale Sprague-Dawley rats (n 68) that weighed between
225 and 250 g were obtained from Charles River Laboratories. Rats were
housed in groups of two in plastic tubs with standard bedding and with
food and water available ad libitum, except during experimental proce-
dures. The temperature in the colony wasmaintained at 22°C with a 12 h
reversed light/dark cycle. Animals were allowed at least 1 week to accli-
mate to the colony before any procedures were performed. The Institu-
tional AnimalCare andUseCommittee of theUniversity of Pennsylvania
approved all procedures with animals.
Drugs. Deoxycorticosterone acetate (DOC; Sigma-Aldrich) was ad-
ministered subcutaneously (s.c.) at a dose of 0.25 mg in 0.2 ml of sesame
oil (Sigma-Aldrich). DOC is typically used instead of aldosterone be-
cause it penetrates the blood brain barrier more easily than aldosterone
because of its low capacity for hydrogen bond formation (Geerling and
Loewy, 2009). Sesame oil was administered at 0.2 ml subcutaneously as a
control. The specific doses for each drug given intracerebroventricularly
were as follows: 2.0 or 20.0 ng AngII in a volume of 2.0 l (Bachem), 2.0
nmol U0126 dissolved in 10% DMSO in a volume of 2.0 l (Promega),
20.0 ng xestospongin-C (XC) dissolved in 2% DMSO in a volume of 2.0
l (Tocris Bioscience), 8.5 nmol/side of 2% lidocaine in a volume of 0.4
l (Phoenix Pharmaceuticals), 10.0 g oxytocin in a volume of 1 l
(Bachem; catalog # H-2510). Artificial CSF (aCSF; R&D Systems) plus
10%DMSOwas administered intracerebroventricularly as a vehicle con-
trol in a volume of 2.0 l.
Surgeries. Surgeries were performed in aseptic conditions. Animals
were anesthetized with isofluorane gas before being fixed in a stereotaxic
frame and implanted with a 26 gauge guide cannulae (Plastics One)
aimed at the lateral ventricle. For the lateral ventricle surgeries, coordi-
nates were as follows: 0.48 mm caudal to bregma, 1.6 mm frommid-line
and 4.2 mm ventral to dura mater. For the lidocaine experiments, an
additional 26 gauge double-guide cannula (0.8mmapart) was implanted
into the PVN. For PVNdouble cannulae, coordinates were as follows: 1.8
mm caudal to bregma, 0.4 mm from themid-line, and 7.7 mm ventral to
duramater. These coordinates were chosen to allow an internal injection
cannula to extend beyond the guide cannula into either the ventricular
space or the PVN itself. The cannulae were fixed in place with dental
cement and bone screws, and the animals were allowed at least 5d to
recover before verification procedures were performed. After surgery,
animals were injected with yohimbine (0.11 mg/kg, Ben Venue Labora-
tories). Upon awakening, animals were singly housed.
Five days after surgery and before undergoing experimental treat-
ments, animals were tested for correct lateral ventricle cannula place-
ment and patency. They were given an intracerebroventricular injection
of 20.0 ng of AngII diluted in aCSF via a Hamilton syringe connected
with PE-10 tubing to an injector that terminated 1mmbeyond the guide
cannula. Animals were excluded from the experiment if they failed to
demonstrate a drinking response in 30 s consuming at least 3 ml of
water in two separate AngII challenges. Animals began behavioral testing
3 d after the intracerebroventricular test injections.
Behavioral studies.Rats were placed in individual wiremesh-bottomed
cages withwater and food available ad libitum. One day before injections,
rats acclimated for 1 h to two 25ml bottles containing tapwater and 1.5%
saline, each marked with 0.2 ml graduations. Vehicle or DOC (0.25 mg)
was administered to each rat in 0.2 ml of sesame oil twice daily (10 h
apart) for 3 d.
To investigate the role of ERK1/2 in this model of water and sodium
consumption, rats were assigned to specific intracerebroventricularly
conditions on the fourth day: vehicle, U0126, AngII, or U0126 plus An-
gII. U0126 was administered 15 min before AngII in the last condition
(Daniels et al., 2009; Felgendreger et al., 2013). To examine the role of the
OVLT activation in the potentiation of sodium appetite, rats were as-
signed to specific intracerebroventricular conditions on the fourth day:
vehicle, XC, AngII, or XCplusAngII. XCwas administered 20min before
AngII in the last condition (Brennan et al., 2008; Li et al., 2011). To
evaluate the role of the PVN in DOC and AngII-induced sodium appe-
tite, rats were administered either vehicle or lidocaine directly into the
PVNover the course of 1min, followed 5min later by injection of vehicle
or AngII intracerebroventricularly (Flanagan et al., 1992; Fernandes et
al., 2007). The bilateral lidocaine injection was performed using a dual
infusion pump (Harvard Apparatus). In an additional study examining
the role of oxytocin in sodium appetite, oxytocin or vehicle was admin-
istered intracerebroventricularly15 min before injections of lidocaine
and AngII (Blackburn et al., 1992b).
For all behavioral experiments, after the last drug treatment was given,
rats were returned to their cages, and water and saline levels were mea-
sured at 15min intervals for the first hour and then at 30min intervals for
the next hour. Food was not available during behavioral testing.
Western blot. Animals were pretreated twice daily for 3 d (10 h apart)
with vehicle or DOC, as described above. On day 4, rats were adminis-
tered either vehicle, 2 ng AngII, or 20 ng AngII intracerebroventricularly.
Two minutes after the last injections, animals were rapidly decapitated
and brains were flash frozen in hexane over dry ice. Using a cryostat, 1
mm punches of brain regions of interest (OVLT, SFO, PVN, SON) were
collected from 300 m slices. The OVLT and SFO were combined and
the PVN and SON punches were combined from each rat to ensure
sufficient tissue. Punches were immersed in lysis buffer containing 25
mM Tris-HCl, pH 8, protease inhibitors (pepstatin, leupeptin, apro-
tinin), and phosphatase inhibitors (sodium pyrophosphate, sodium
fluoride, sodiummolybdate, phenylarsin oxide, and sodium orthovana-
date). The OVLT/SFO and PVN/SON punches were immersed in 50 and
100 l of lysis buffer, respectively. Brain punches were sonicated for 3 s
followed by centrifugation at 14,000 rpm in 4°C for 15 min. Supernatant
was collected and a bicinchoninic acid (BCA) protein assay was per-
formed on 5 l of each sample. Based on the protein levels detected by
BCA, appropriate amounts of sample and sample buffer were loaded into
wells of a SDS polyacrylamide gel. Western blot for phospho- and total-
ERK1/2 was performed using the LiCor Odyssey System. The following
antibodies were used: phospho-ERK1/2 (Thr202/Tyr204; E10) Mouse
mAb no. 9106 (Cell Signaling Technology); Erk 1 Antibody (C-16): sc-93
(Santa Cruz Biotechnology); IRDye 800CW Goat anti-Mouse IgG (H
L; Li-Cor Biosciences); IRDye 680LT Goat anti-Rabbit IgG (H  L; Li-
Cor Biosciences).
Immunohistochemistry. To observe brain activation after DOC and
AngII treatments, ratswere pretreated twice daily for 3 d (10 h apart)with
vehicle or DOC. On day 4, rats were administered either vehicle or 20 ng
AngII intracerebroventricularly. To determine the efficacy of XC in
blocking calcium release, rats were injected intracerebroventricularly
with vehicle, XC, AngII, or XC plus AngII. To examine the effect PVN
inactivation on cFos expression in other brain areas, rats were injected
with either: lidocaine or vehicle in the PVN, followed 5 min later by
either: vehicle or 20 ng AngII intracerebroventricularly. Sixty minutes
after the last intracerebroventricular injection in each study, each rat was
anesthetized with 50 mg/kg ketamine and 20 mg/kg xylazine, intra-
peritoneally (i.p.). They were perfused transcardially with 100 ml of
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heparinized saline followed by 200 ml 4% paraformaldehyde (Electron
Microscopy Sciences). The brains were isolated, postfixed in paraformal-
dehyde overnight at 4°C, then submerged in 20% sucrose in 0.1 M phos-
phate buffer for 3 d. Coronal sections were cut on a freezing microtome
into three serial sets of 40-m-thick sections. These slices encompassed
the OVLT, SFO, PVN, and SON. One set from each animal underwent
immunohistochemical staining and analysis. Rostral-caudal coordinates
(relative to bregma) for each brain region analyzed are as follows:
OVLT  0.60 mm to 0.12 mm; SFO  0.60 mm to 1.44 mm;
PVN  1.56 mm to 1.92 mm; SON  0.48 mm to 1.32 mm.
These correspond to specific figures in the rat brain atlas (Paxinos and
Watson, 1986; OVLT  their Figs. 28–32, SFO  their Figs. 38–45,
PVN  their Figs. 46–49, SON  their Figs. 37–44. OVLT sections
include the dorsal cap and lateral margins as previously described (Old-
field et al., 1994; Bisley et al., 1996). Sections were matched to these atlas
coordinates, with four to six sections total per brain region within each
animal and six animals per treatment group.
For cFos immunohistochemistry, sections were washed in Tris-
buffered saline (TBS), pH 7.4, then incubated with a cFos antibody (1:
500, sc-52, rabbit; Santa Cruz Biotechnology) in TBS with 0.2% Triton
X-100 and 3% normal donkey serum (Jackson Immunoresearch) over-
night at 4°C. After several washes, sections were incubated with a biotin-
SP-conjugated AffiniPure donkey anti-rabbit IgG (1:100, Jackson
Immunoresearch) in TBS with 0.2% Triton X-100 and 3% normal don-
key serum for 2 h at room temperature. After several washes, sections
were incubated with the Vectastain ABC kit (Vector Laboratories) for
1 h. This was followed by another set of washes before staining with
33-diaminobenzidine (Sigma-Aldrich) for 10 min. After a final set of
washes, sections were mounted on slides, air-dried, and coverslipped
with DPX mounting media (Electron Microscopy Sciences).
A subset of sections including theOVLTwas double-labeled forAngII-
induced cFos and oxytocin immunohistochemistry. Immunohisto-
chemistry was performed as previously described, except with another
cFos primary antibody (1:500, sc-8047, mouse, Santa Cruz Biotechnol-
ogy) and an oxytocin antibody (1:500, T-4084, rabbit; Bachem). The
specificity of cFos has been previously reported (Hebert et al., 2005). The
oxytocin antibody was raised against the nonapeptide oxytocin (H-Cys-
Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2). Radioimmunoassay data pro-
vided by the manufacturer reported 100% and 0% cross-reactivity for
oxytocin and vasopressin, respectively. We performed additional speci-
ficity tests previously (Griffin et al., 2010), including omission of the
primary or secondary antisera, preabsorption with the oxytocin peptide,
and the lack of labeling in oxytocin knock-out mice, unlike the sections
fromwild-type littermates stained in parallel. The lack of cross-reactivity
between the labeling of each primary antiserum was verified by the cel-
lular compartmental specificity of cFos versus oxytocin labeling when
each was labeled individually: cFos was never observed in fibers, and
oxytocin was never localized to the nucleus. The secondary antibodies
used for this staining were biotin-SP-conjugated AffiniPure donkey anti-
mouse IgG and donkey-antirabbit IgG (1:100, Jackson Immunore-
search).
Images were acquired with a digital camera (Diagnostic Instruments,
model RTKE), maintaining the same microscope and camera settings to
ensure the same level of light and exposure for all images. Background
was subtracted from images using Photoshop, and images were thresh-
olded to the same level (200). Images were further analyzed in NIH
ImageJ using standardized boxes for each brain region (calculated using
the rat brain atlas; Paxinos andWatson, 1986), using the analyze particles
function. Pixel size minimum was 15 and circularity was set to 0.35. All
image analysis was performed with the experimenter blind to the treat-
ment groups.
Oxytocin secretion. Animals were pretreated twice daily for 3 d with
vehicle or DOC, as described previously. On day 4, rats were adminis-
tered either vehicle or 20 ng AngII intracerebroventricularly. Two min-
utes after the last injections, animals were rapidly decapitated and trunk
blood was collected into 10 ml BD Vacutainer blood collection heparin-
ized glass tubes on ice. The tubes then were centrifuged at 4°C at 1300
relative centrifugal force for 10 min. The plasma supernatant was ex-
tracted with acetone and petroleum ether. Plasma levels of oxytocin and
AVPweremeasured with a specific radioimmunoassay performed by the
laboratory of Dr Joseph G. Verbalis, as described previously (Verbalis et
al., 1986). The standard curve for each peptide was linear between 0.25
and 5 U per tube with the oxytocin standard and between 0.5 and 10.0
pg per tube using a synthetic AVP (Bachem Americas). The minimum
detectable concentration of oxytocin or AVP in extracted plasma was
0.25 U/ml and 0.5 pg/ml, respectively. The oxytocin antiserum exhib-
ited 1% cross-reactivity with AVP, and the AVP antiserum (R-4) dis-
played1% cross-reactivity with oxytocin.
Statistical analysis. Data are presented as the mean  SEM. For all
experiments, comparisons were made between treatment groups (with
either a one-way, two-way, or three-way ANOVA). When warranted,
planned comparison post hoc t tests were performed. All hypothesis
tests used   0.05 as the criterion level of significance. Statistical
analyses were conducted using Prism 2.0 software for one-way or
two-way ANOVAs and Statistica 12 Ultimate Academic Bundle for
three-way ANOVAs.
Results
The role of ERK1/2 in DOC and AngII-induced
sodium appetite
Consistent with previous research (Fluharty and Epstein, 1983),
DOC pretreatment potentiated AngII-induced sodium intake,
but not water intake (Fig. 1A). A two-way ANOVA established a
main effect for both AngII (F(2,54)  10.7, p  0.001) and DOC
(F(1,54) 29.6, p 0.001) on sodium intake, as well as an inter-
action between the two treatments (F(2,54) 3.2, p 0.046; n
12 rats/treatment group). Bonferonni post hoc t tests revealed a
significant difference between each dose of AngII and the respec-
tive DOC pretreated condition (p  0.001 for the 2 ng AngII
dose; p 0.020 for the 20 ngAngII dose). Regardingwater intake,
a two-way ANOVA supported a main effect for AngII (F(2,60) 
31.1, p  0.001), but not DOC (F(1,60)  0.7, p  0.400), to
increase water intake.
The role of ERK1/2 in the interaction betweenAngII andDOC
to induce sodium appetite was investigated by using the MEK
inhibitor U0126 (Fig. 1B). A three-way ANOVA indicated that
there was no interaction between all three variables on sodium
intake (F(1,153) 1.5, p 0.222). However, there was an interac-
tion between DOC and AngII (F(1,153)  8.1, p  0.001), as re-
ported in Figure 1A. Additionally, there was an interaction
between theMEK inhibitor and AngII (F(1,153) 3.1, p 0.050).
Specifically, U0126 significantly reduced sodium intake induced
by 20 ng AngII alone (6.6  1.8 vs 2.2  1.0 ml, p  0.003;
planned comparison t tests; n  18 rats/treatment group), as
shown previously (Daniels et al., 2009; Felgendreger et al., 2013).
However, the MEK inhibitor U0126 did not reduce sodium in-
take elicited by combinedDOC and AngII treatments; in the 2 ng
AngII condition, U0126 enhanced DOC/AngII induced sodium
appetite (5.1 0.9 vs 8.5 0.8 ml, p 0.010, for the 2.0 ng dose
of AngII; 11.3 1.4 vs 12.6 2.3ml, p 0.270, for the 20 ng dose
of AngII). U0126 did not diminish the effect of AngII on water
consumption.
The effect of these hormonal treatments on the activation of
ERK1/2 in OVLT, SFO, PVN, and SON then was measured by
Western blot analysis, as shown in Figure 1C.A two-wayANOVA
supported a main effect of AngII alone, but not DOC alone, on
ERK1/2 phosphorylation (F(2,20)  4.1, p  0.030; n  6 rats/
treatment group) for both OVLT/SFO and PVN/SON. Post hoc
tests revealed that both doses of AngII significantly increased
phospho-ERK1/2 comparedwith vehicle treatment (OVLT/SFO:
0.5  0.0 and 0.5  0.0 vs 0.3  0.0, p  0.049 and 0.043);
PVN/SON: 0.5  0.0 and 0.4  0.0 vs 0.3  0.0, p  0.025 and
0.048). Additionally, there was a significant interaction between
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DOC and AngII treatments for these brain regions (OVLT/SFO:
F(2,20) 4.1, p 0.031; PVN/SON: F(2,20) 3.9, p 0.035), such
that in the presence of DOC, AngII treatment no longer activated
ERK1/2. In short, these results did not support the hypothesis
that DOC potentiated the effects of central AngII on sodium
appetite by further increasing phospho-ERK1/2 levels in relevant
brain regions. Nevertheless, the negative interaction between
DOC and AngII on ERK1/2 activation in circumventricular and
neuroendocrine regions suggested that further investigation of
these areas was warranted.
The interaction of DOC and AngII on cFos activation in
the brain
To further explore the neurologicalmechanisms that underlie the
behavioral cooperativity of DOC and AngII, cFos immunohisto-
chemistry was used to detect a unique pattern of brain activity
Figure 1. Erk1/2 is not necessary for the DOC/AngII potentiation of sodium appetite. A, Bar graphs illustrating the potentiation of AngII-induced sodium but not water intake by DOC (n
12/group).B, Bar graphs illustrating the effect of blocking ERK1/2activationonDOCandAngII-induced sodiumandwater intake (n18/group). DOCpotentiated2and20ngAngII-induced sodium
intake. This behavior was not reduced by the MEK inhibitor U0126; however, U0126 reduced sodium intake with 20 ng AngII alone. AngII-induced water intake was not potentiated by DOC. C, Bar
graphs illustrating phosphorylated ERK1/2 levels in the OVLT/SFO and PVN/SON after either oil or DOC pretreatment followed by intracerebroventricular treatments with 2 or 20 ng AngII (n
6/group). AngII treatment induced significant ERK1/2 phosphorylation compared with vehicle in both sets of brain regions. DOC pretreatment did not enhance this activation. Representative
Western blot images of ERK1/2 phosphorylation are shown above each quantified bar. For the sake of clarity, only specific statistical differences are highlighted. “A” indicates AngII is different from
vehicle; “B” indicates DOC/AngII is different from AngII; “C” indicates U0126/AngII is different from AngII; and “D” indicates U0126/DOC/AngII is different from DOC/AngII, p 0.05. Veh, Vehicle.
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that might correspond to the behavioral effects of these hor-
mones. As illustrated in Figure 2A, brain sections from OVLT,
SFO, PVN, and SONwere analyzed for cFos immunolabeling. In
the OVLT, a two-way ANOVA revealed a main effect for both
AngII and DOC on cFos expression (F(1,17)  16.4, p  0.001;
F(1,17)  12.8, p  0.002; n  6 rats/treatment group, 4–6 sec-
tions per brain area). Bonferonni post hoc tests indicated that cFos
levels were significantly enhanced compared with vehicle for all
treatment groups (vehicle: 8.7  1.9, DOC: 30.2  6.3, AngII:
32.7 4.4, DOC andAngII: 49.3 6.0; p 0.021, p 0.003, p
0.001). In the SFO, a two-wayANOVA indicated amain effect for
AngII on cFos expression (F(1,16) 32.5, p 0.001). Bonferonni
post hoc tests noted that cFos levels were similar for vehicle and
DOC, but both AngII and DOC/AngII treatments significantly
enhanced staining (vehicle: 11.5 2.6, DOC: 22.1 6.0, AngII:
56.8 5.9, DOC andAngII: 47.4 7.6; p 0.200, p 0.001, p
0.004). In the PVN, a two-way ANOVA revealed amain effect for
AngII, DOC, and an interaction between the two variables on
Figure 2. DOC pretreatment enhanced AngII-induced OVLT activation and reduced PVN activity and oxytocin (OT) release.A, Bar graphs illustrating cFos cell counts in different brain areas (OVLT,
SFO, PVN, and SON) after either vehicle or DOC pretreatment followed by intracerebroventricular vehicle or 20 ng AngII (n 6/group). In the OVLT, each treatment condition induces cFos
immunostaining compared with vehicle; DOC/AngII induced additional cFos immunostaining. In the SFO, both AngII alone and DOC/AngII induced more cFos staining than either vehicle or DOC
alone. cFos labeling in the PVN was increased by AngII, but DOC reduced the AngII-induced cFos expression to control levels. In the SON, AngII induced cFos staining. Representative images of the
OVLT and PVN (coronal plane, 10) in each treatment condition are shown above the bar graphs. Representative images of SFO and SON are not shown, but similar data were seen. B, Bar graphs
illustrating oxytocin and AVP plasma levels after either vehicle or DOC pretreatment followed by intracerebroventricular vehicle or 20 ng AngII (n 8/group). AngII treatment increased oxytocin
levels, and this effect was reduced by DOC pretreatment. However, AngII treatment elevated AVP levels, regardless of pretreatment. For the sake of clarity, only specific statistical differences are
highlighted. “A” indicates AngII is different from vehicle; “B” indicates DOC/AngII is different from AngII. Veh, Vehicle.
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cFos expression (F(1,18) 16.4, p 0.001; F(1,18) 7.5, p 0.014,
F(1,18) 7.0, p 0.016). Bonferonni post hoc tests indicated that
AngII significantly increased cFos staining comparedwith vehicle
in the PVN (126.3  5.3 vs 59.4  6.9, p  0.001), and DOC
reduced AngII-induced cFos staining to vehicle levels (126.3 
5.3 vs 72.5  14.4, p  0.006). In the SON, a two-way ANOVA
revealed amain effect for AngII on cFos expression (F(1,16) 7.9,
p 0.013). Post hoc tests indicated that AngII induced a signifi-
cant amount of cFos staining compared with vehicle (40.4 6.6
vs 14.6 3.7, p 0.020). There was a trend for DOC to reduce
AngII-induced Fos staining compared with AngII alone (25.4
5.0 vs 40.4 6.6, p 0.100). In short, the most striking interac-
tions between DOC and AngII on cFos labeling were the en-
hanced cFos staining in the OVLT and the suppressed cFos levels
in the PVN.
The observation that DOCdiminished the AngII-induced Fos
activation in the PVN is reminiscent of previous studies that
demonstrated that DOC inhibits oxytocin neuron activity in the
PVN, thereby disinhibiting sodium intake (Roesch et al., 2001).
We tested whether the DOC treatment was associated with alter-
ations inAngII-induced neurohypophysial secretion. Plasma lev-
els of oxytocin and AVP were measured by radioimmunoassay
after DOC, AngII, or both hormone treatments, 2 min after the
AngII treatment (Fig. 2B). A two-way ANOVA revealed a main
effect for both AngII and DOC, as well as an interaction between
the two hormones on oxytocin secretion (F(1,27) 4.2, p 0.049;
F(1,27)  4.4, p  0.045; F(1,27)  5.7, p  0.020, n  8 rats/
treatment group).AngII increasedoxytocin levels significantly com-
pared with vehicle (12.8 2.9 vs 6.4 0.8 pg/ml, p 0.048). DOC
reduced these AngII-induced oxytocin levels back down to control
levels (12.8 2.9 vs 5.1 1.2 pg/ml, p 0.035). In contrast, there
was no effect of DOC on AngII-induced AVP secretion.
Together, these results demonstrate parallel changes in cFos
expression in the OVLT, PVN oxytocin activity, and the natri-
orexic effect of combined DOC and AngII. We next sought to
determine whether disruption of cFos induction in the OVLT
with an IP3 receptor antagonist would impair the behavioral co-
operativity of DOC and AngII.
The role of IP3 in DOC and AngII-induced sodium appetite
IP3 signaling was blocked with an antagonist to the IP3 receptor,
namely XC. First the bioactivity of centrally administered XCwas
verified by assaying AngII-induced cFos immunohistochemistry
in Figure 3A. Given that cFos is an immediate early gene activated
by IP3-induced intracellular calcium signaling, an effective IP3
receptor antagonist should prevent calcium signaling, and
thereby cFos expression (Clark et al., 1992; Templeton et al.,
1998; Jomphe et al., 2003; Daniels et al., 2005; Zhang et al., 2012).
A two-way ANOVA indicated main effects of AngII and XC, and
an interaction on cFos expression (F(1,17) 6.0, p 0.026; F(1,17)
 6.0, p  0.026; F(1,17)  5.7, p  0.029; respectively) in the
OVLT (n 6 rats/treatment group, 4–6 sections per brain area).
In particular, Bonferroni post hoc tests suggest that XC pretreat-
ment significantly reduced the number of AngII-induced cFos-
labeled neurons (35.8 5.2 vs 11.7 1.6, p 0.002). Labeling in
the SFO exhibited a main effect for AngII, but not XC (F(1,15)
7.2, p  0.020; F(1,15)  0.9, p  0.360). However, there was a
significant interaction between AngII and XC (F(1,15) 5.3, p
0.040). Specifically, Bonferonni post hoc tests designated a signif-
icant reduction in cFos expression between AngII and XC plus
AngII (30.0 4.3 vs 15.1 4.3, p 0.035).
Having demonstrated that the XC treatment effectively
blocked IP3-induced cFos in relevant brain regions, the role of
IP3 in AngII and DOC induced sodium appetite was investigated
(Fig. 3B). A three-way ANOVA indicated that sodium intake
differed between treatment groups (F(1,68) 6.5, p 0.010; n
10 rats/treatment group). Consistent with Figure 1, DOC en-
hanced AngII-induced sodium intake (p  0.006). XC did not
affect sodium ingestion in animals treated with AngII alone
(8.3 1.8 vs 8.3 1.7 ml, p 0.990). However, XC reduced the
DOC and AngII enhancement of sodium intake to levels similar
to the AngII alone group (15.1 1.3 vs 10.9 1.3ml, p 0.030).
Likewise, a three-way ANOVA revealed that water intake differed
between treatment groups (F(1,51) 5.8, p 0.020). Post hoc tests
indicated that XC reduced AngII-induced water intake (11.0 
1.6 vs 6.9  1.0 ml, p  0.030). However, when both DOC and
AngII were present, XC did not reduce water intake (8.7 1.1 vs
9.2 1.8 ml, p 0.810). Together, these results suggest that IP3
signaling, possibly in the OVLT, is necessary for the cooperative
actions of DOCA and AngII on sodium appetite. Previous work
suggested that DOC enhances AngII-induced sodium appetite
via the suppression of oxytocin activity in the PVN (Stricker and
Verbalis, 1987; Blackburn et al., 1992a), and several findings re-
ported here are consistent with that hypothesis. Therefore, the
next experiment was designed to manipulate PVN activity and
measure the effect on sodium appetite and neuronal activation in
the OVLT.
Sodium appetite and OVLT activation after suppression of
PVN activity
Neural activity in the PVN was suppressed with bilateral injec-
tions of lidocaine above the PVN. Behavioral analysis included
only animals with cannula tract locations verified to be above the
PVN (Fig. 4A). Animals were treated with either vehicle or lido-
caine into the PVN, followed by either vehicle or AngII (20 ng,
i.c.v.). A two-way ANOVA revealed a main effect for AngII and
lidocaine, as well as an interaction on sodium intake (F(1,20) 
21.5, p 0.001; F(1,20) 5.2, p 0.035; F(1,20) 6.7, p 0.020;
n  10 rats/treatment group). As shown in Figure 4B, AngII
increased sodium intake compared with vehicle (5.6  1.0 vs
2.0 0.6ml, p 0.040). Additionally, lidocaine enhancedAngII-
induced sodium intake significantly (9.5  1.2 vs 5.5  1.4 ml
p 0.045). Conversely, a two-wayANOVArevealed amain effect
for AngII but not lidocaine on water intake (F(1,23)  28.8, p 
0.0001; F(1,23) 0.1, p 0.740). Post hoc tests denoted AngII plus
or minus lidocaine-treated rats drank very similar amounts of
water (9.1  1.5 vs 8.6  1.0 ml, p  0.760), but both groups
drank significantly more than vehicle-treated rats (0.5 0.5 ml,
p 0.02 and p 0.009). A subset of rats was treated with oxyto-
cin (10.0g, i.c.v.) in the lidocaine plus AngII condition. Oxyto-
cin coadministration decreased sodium intake to vehicle levels
(9.5 1.2 vs 2.1 0.7 ml, p 0.001). However, oxytocin treat-
ment also partially decreased water intake in the lidocaine plus
AngII group (8.6 1.0 vs 4.7 1.2 ml, p 0.030). In summary,
lidocaine in the PVN enhanced AngII-induced sodium intake,
but notwater intake,mimicking the effects ofDOCpretreatment.
After the behavioral studies, AngII-induced cFos immunohis-
tochemistry was performed on the brains of these animals to
verify the efficacy of lidocaine administration to the PVN and to
test the hypothesis that PVN activity may restrain sodium appe-
tite by inhibiting neural activity in the OVLT (Fig. 4C). Based on
the behavioral results, these treatments were selected for compar-
ison: vehicle/vehicle; vehicle/AngII; and lidocaine/AngII. One-
wayANOVA indicated that cFos expression in theOVLTdiffered
between treatment groups (F(2,21)  34.47, p  0.001; n  6
rats/treatment group, 4–6 sections per brain area). Post hoc tests
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indicated that lidocaine further enhanced 20 ng AngII-induced
cFos expression in the OVLT (33.29  3.0 vs 54.60  3.0, p 
0.001), emulating the effects seen with DOC pretreatment. Addi-
tionally, cFos expression in the PVN was reduced with lidocaine
pretreatment, illustrating reduced PVN activity (140.6 15.6 vs
88.5 3.5, p 0.010).
The previous experiments implicate the OVLT in the control
of sodium appetite, in possible relation with centrally released
oxytocin, a key inhibitor of sodium appetite. Although oxytocin
receptor mRNA has been described in the OVLT (Yoshimura et
al., 1993), the physiological delivery of oxytocin to the OVLT
remains unclear. As shown in Figure 5, varicose oxytocin-
immunoreactive fibers are present in theOVLT. In particular, the
oxytocinergic fibers are abundant in the dorsal cap of the OVLT
in close associationwith neurons expressing AngII-induced cFos.
Discussion
Classic studies showed that AngII and adrenal steroids work co-
operatively to elicit a robust salt appetite when elevated concur-
rently, as occurs during hypovolemia and sodium depletion
(Stricker and Wolf, 1966; Stricker, 1966, 1971; Epstein, 1982;
Toth et al., 1987). This potentiation of sodium appetite has been
observed in various species and is not secondary to natriuresis
(Fluharty and Epstein, 1983; Massi and Epstein, 1990; Shade et
al., 2002). Experiments with agonists and antagonists confirmed
the validity of the “synergy hypothesis” in situations in which the
appetite was associated with elevated endogenous levels of AngII
and aldosterone (Sakai et al., 1986). The present report initially
tested the hypothesis that DOC and AngII actions converge on
the ERK1/2 signaling pathway, given that adrenal steroids can
Figure 3. The IP3 receptor is required for DOC/AngII potentiation of sodium appetite. A, Bar graphs illustrating the level of cFos expression in the OVLT and SFO after vehicle, XC, 20 ng AngII, or
XC plus 20 ng AngII intracerebroventricularly (n 6/group). Representative images of cFos staining of OVLT coronal sections (10) in each treatment group are shown above the graphs.
Representative images of the SFO are not shown, but similar data were seen. AngII induced cFos staining in both the OVLT and SFO, and the effect was reduced by XC. B, Bar graphs illustrating the
effect of XC onDOC and 20 ngAngII induced sodiumandwater intake (n 10/group). DOC potentiates AngII-induced sodium intake; this effectwas impaired by the IP3 receptor inhibitor XC. XC did
not affect sodium intake induced by AngII alone. AngII-induced water intake was reduced by XC. For the sake of clarity, only specific statistical differences are highlighted. “A” indicates AngII is
different from vehicle; “B” indicates DOC/AngII is different fromAngII; “C” indicates XC/AngII is different fromAngII; “D” indicates XC/DOC/AngII is different fromDOC/AngII; p 0.05. Veh, vehicle.
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Figure 4. PVN inactivation enhances AngII-induced sodium appetite. A, Illustration of rat coronal brain slices depicting bilateral guide cannula placements (filled circles) above the PVN for
lidocaine administration. Each pair of dots represents data from one animal. B, Bar graphs illustrating the effect of intra-PVN lidocaine on 20 ng AngII-induced sodium and water intake (n
10/group). Lidocaine-treated animals increased their AngII-induced sodium intake, but notwater intake,mimicking the effects of DOC.C, Bar graphs illustrating cFos expression in theOVLT andPVN
after vehicle, lidocaine, 20 ng AngII, or lidocaine plus 20 ng AngII intracerebroventricularly (n 6/group). Representative images of cFos staining of OVLT and PVN coronal sections (10) in each
treatment group are shown above the graphs. AngII-induced cFos immunostaining was enhanced by lidocaine in the OVLT and reduced in the PVN. For the sake of clarity, only specific statistical
differences are highlighted. “A” indicates AngII is different from vehicle; “B” indicates lidocaine/AngII is different from AngII. Veh, Vehicle.
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increase AT1R expression (Ullian et al., 1992; Harada et al., 2001;
Mazak et al., 2004) and enhance their cellular signaling (Lemarie´
et al., 2008, 2009). However, behavioral and biochemical studies
did not support this hypothesis. Rather, IP3 signaling,whichdidnot
mediate the sodium appetite induced by either hormone alone, was
necessary for the behavioral cooperation. Functional neuroanatomy
analysis revealed that the combinedDOC andAngII treatment sup-
pressed cFos activation in the PVN, reduced neurosecretion of oxy-
tocin, and augmented cFos expression in the OVLT. This led to the
novel hypothesis thatDOC-induced suppression of oxytocin neural
activity in the PVN relieves inhibition in theOVLT to allow a robust
sodium ingestion. Local lidocaine administration into the PVN,
which prevented AngII-induced cFos expression in the PVN, con-
comitantly elevated sodium appetite and cFos activation in the
OVLT. Finally, immunohistochemical analysis demonstrated that
theOVLT iswell suppliedwith oytocin fibers, especially in the vicin-
ity of AngII-induced cFos expression. Thus, the present studies pro-
vide further support for an inhibitory signal arising from the
oxytocin neurons in PVN and provide novel evidence that oxytocin
may act in the OVLT.
Lack of support for an amplification of ERK1/2 signaling
Central AngII administration activates ERK1/2 in the SFOandPVN
(Wei et al., 2009), and ERK1/2 signaling is specifically required for
the sodium appetite that emerges after exogenous AngII treatment
(Daniels et al., 2005) and endogenous AngII production (Felgend-
reger et al., 2013). Thus,we hypothesized that ERK1/2 alsowould be
critical for the cooperative effect of DOC and AngII on sodium in-
take. Behavioral pharmacology and signaling biochemistry experi-
ments, although replicating the previous finding of AngII-induced
ERK1/2 and ERK1/2-dependent sodium appetite, did not support a
role for ERK1/2 in the combined effect of DOC and AngII. One
interpretationof this result is thatDOCremovesboth excitatory and
inhibitory effects of AngII. On the contrary, DOC enhances AngII-
induced cFos expression in the OVLT, suggesting that at least some
excitatory effects of AngII remain andmay contribute to the behav-
ioral synergy.
The interaction of DOC and AngII on IP3-mediated
cFos induction
The AT1R is coupled with intracellular IP3 formation (Smith et
al., 1984; Enjalbert et al., 1986; Taylor et al., 1990; Beresford and
Fitzsimons, 1992), which in turn acts on the IP3 receptor on the
endoplasmic reticulum to liberate intracellular calcium as a third
messenger (Nabika et al., 1985; Capponi et al., 1988; Sua´rez et al.,
2002). One consequence of calciummobilization is transcription
of immediate early genes, including cFos (Clark et al., 1992;
Templeton et al., 1998; Jomphe et al., 2003; Daniels et al., 2005;
Zhang et al., 2012). Central administration of AngII activates
cFos expression in several brain regions, including the OVLT,
SFO, PVN, and SON(Blackburn et al., 1992a;Herbert et al., 1992;
McKinley et al., 1992a), as replicated here. In agreement with
previous work (Blackburn et al., 1992a), DOC pretreatment di-
minished AngII-induced cFos in the PVN and oxytocin neurose-
cretion. The novel finding that DOC pretreatment increases
cFos expression in the OVLT represents a striking parallel with
the behavioral effects of DOC and AngII on sodium ingestion.
The OVLT is included in the region referred to as the antero-
ventral third ventricle, and partial damage to this region dis-
inhibits sodium appetite (Andersson et al., 1975; Gardiner et
al., 1986; Fitts et al., 1990; Fitts, 1991). IP3 receptor activation
was necessary for the DOC and AngII cooperativity on sodium in-
take, without affecting the sodium ingestion stimulated by either
hormone alone.
These three findings may be considered together: (1) the IP3
signaling pathway is uniquely necessary for the DOC and AngII
cooperative effect on sodium appetite; (2) its downstream effec-
tor in the OVLT, cFos, is highest with combined DOC and AngII
treatment, unlike cFos labeling in the other brain regions studied;
and (3) PVN activity and oxytocin release are suppressed during
the cooperative stimulation of sodium appetite. A parsimonious
explanation of these results, partially supported by previous stud-
ies, would be that DOC treatment inhibits oxytocin neurons in
the PVN, which in turn relieves inhibition on a subset of OVLT
neurons, which then augments the drive for sodium ingestion
based on IP3 signaling.
Figure 5. Oxytocin fibers are closely associatedwith AngII-induced cFos in the dorsal cap of the OVLT. A, Representative image of oxytocin and cFos staining of an OVLT coronal section (10) in
an AngII-treated animal. B, Magnified image of the dorsal cap of the OVLT (from the box drawn in A). Thin and thick arrows indicate certain cFos nuclei and OVLT fibers, respectively, that are
juxtaposed throughout the dorsal cap.
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The role of oxytocin in sodium appetite
A model has been proposed in which centrally acting AngII si-
multaneously stimulates and inhibits sodium appetite, with the
inhibition caused by oxytocin release in the brain (Stricker and
Verbalis, 1987, 1996; Blackburn et al., 1992a). Other investigators
also have observed a disinhibition of sodium appetite after cen-
tral administration of an oxytocin antagonist or in knock-out
mice (Chow et al., 1997; Puryear et al., 2001; Fitts et al., 2003),
although the enhancement of the sodium appetite by an oxytocin
antagonist may be somewhat dependent on the dose of AngII
(Fitts et al., 2003; Stricker andVerbalis, 2004). The present results
replicate several key findings, including the dampening of AngII-
induced cFos activation of the PVN and oxytocin release by DOC
pretreatment. However, the site of oxytocin action to inhibit so-
dium appetite had been unknown.
The discovery that DOC treatment uniquely enhanced the
effect of AngII on cFos expression in the OVLT suggests that it is
the target of the oxytocinergic inhibition of sodium appetite.
Indeed, oxytocin receptor mRNA is localized to the OVLT (Yo-
shimura et al., 1993).Here, we have demonstrated oxytocin fibers
disbursed throughout the dorsal cap of the OVLT. The OVLT
includes osmosensitive neurons and is thought to function as the
brain’s primary osmostat (Denton et al., 1996; Johnson et al.,
1996). Many neurons in the OVLT are excited by hypertonicity
and inhibited by hypotonicity (Sayer et al., 1984; Honda et al.,
1990; Vivas et al., 1990; Nissen et al., 1993), mediated by mem-
bers of the transient receptor potential vanilloid proteins (Ciura
and Bourque, 2006). The OVLT sends both GABAergic and glu-
tamatergic projections to a variety of brain regions (Camacho
and Phillips, 1981; Richard and Bourque, 1996), although the
functions of these projections remain ill-defined. The present
results build on this body of work by correlating the suppression
of PVN activity, by either DOC or lidocaine, with increased acti-
vation inOVLTneurons. Given that the natriorexic effect of PVN
inhibition was reversed with central oxytocin administration,
oxytocin is likely the critical inhibitory signal arising from the
PVN. Thus, theOVLT, a key sensor of body fluid parametersmay
also be the target of oxytocin modulation of sodium appetite.
It has been proposed that central oxytocin actions are based
on bulk transmission, such as dendritic release in the PVN (Lud-
wig et al., 2002). Although this mechanism may apply to some
situations, oxytocinergic synaptic contacts have been demon-
strated in the ventromedial hypothalamus (Griffin et al., 2010).
Despite its close proximity to ventricular space, the OVLT has a
generous supply of varicose axons containing oxytocin, suggest-
ing local release. Tract tracing studies will be valuable to identify
the specific population of oxytocin neurons that directly inner-
vate the OVLT.
Our results suggest that oxytocin neurons, rather than auto-
nomic or vasopressin neurons, explain the changes of sodium
appetite after PVN-lidocaine administration. Although lidocaine
administered into the PVN could potentially reduce blood pres-
sure via reduced sympathetic activity and vasopressin release,
hypotension is an unlikely cause of the PVN-lidocaine-induced
sodium appetite. In particular, hypotension would also stimulate
water intake, which did not occur.
Interpretational limitations
The present work focused on the OVLT, SFO, PVN, and SON,
based on previous studies. Brainstem, limbic, gustatory, and
other hypothalamic regions are certainly involved, but their con-
tributions were beyond the scope of this study. Likewise, the
analysis of cFos expression and the pharmacological disruption
of neural activity do not fully address the cascade of information
processing within the broader neural network. Given that many
hypothalamic areas are reciprocally connected, further studies
will be needed to disambiguate the roles that these brain regions
play in promoting and inhibiting sodium appetite.
Conclusions
These results rule out the ERK1/2 signaling pathway as an under-
lying mechanism for DOC-AngII enhancement of sodium appe-
tite. Instead, IP3 signaling is required for the cooperativity of
DOC and AngII. Activity in the OVLT and PVN are inversely
related, suggesting an inhibitory signal from the PVN to the
OVLT. Oxytocin fibers woven throughout the dorsal cap of the
OVLT suggest a direct, inhibitory oxytocin input to the OVLT.
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